Principal Automation Engineer - Warehouse Automation
About the job
- A Bachelor's degree in Chemical, Mechanical, Electrical, or Computer Science or a related discipline and 8 years of applicable automation and/or instrument and control system experience, preferably mostly in drug product; or a Master's degree in Engineering or a related discipline and 6 years of applicable automation and/or instrument and control system experience, preferably mostly in drug product.
- Five years of pharmaceutical or biotechnology industry/GMP experience is highly preferred.
- Participate in an on-call environment to meet business continuity requirements, including weekends and holidays as required.
- Proficiency in troubleshooting programmable logic controllers (PLCs), using Siemens TIA Portal or Rockwell Automation, and their communication protocols, including Profinet or EtherNet/IP.
- Strong understanding of SAP Extended Warehouse Management (EWM) or similar warehouse management system (WMS) interfaces, including IDocs, queues, and remote function calls (RFCs).
- Familiarity with automated guided vehicle (AGV) navigation technologies, including laser, natural, or magnetic navigation, and fleet management system (FMS) software.
- Ability to work in a high-density warehouse environment, which may include working at heights or near moving automated machinery.
- Provide on-call support for 24/7 warehouse operations.
- Participate in greenfield project execution and support the facility after it goes live.
- Monitor daily performance of the Körber K.One.X Warehouse Control System (WCS) and automated storage and retrieval systems (AS/RS), proactively identifying stuck telegrams or queue bottlenecks before they affect production output.
- Serve as the highest internal escalation point for complex automation failures and troubleshoot handshakes between programmable logic controller (PLC) layers and the WCS to resolve hardware-software mismatches in real time.
- Maintain and periodically test recovery procedures for the WCS and PLC configurations to restore warehouse flow rapidly after server or network failure.
- Manage daily operational readiness of the automated guided vehicle (AGV) fleet, overseeing battery health, charging station rotations, and sensor calibration to target 99% or greater fleet availability.
- Adjust fleet management system (FMS) parameters, such as zone blocking, speed limits, and path priorities, based on daily operational volumes to prevent congestion in high-traffic corridors.
- Conduct routine operational audits of AGV safety fields and emergency stop circuits to keep equipment within its validated safety envelope.
- Manage site robotics fleet management systems in partnership with future robotics functions at the site.
- Monitor SAP EWM-to-WCS message logs, including IDocs and web services, and resolve data discrepancies so that physical pharmaceutical stock locations match their digital records in SAP.
- Ensure automated logs and event data required by 21 CFR Part 11 are accurately captured, archived, and available for regulatory inspections and quality audits.
- Analyze overall equipment effectiveness (OEE) data from WCS and AGV systems and propose logic adjustments to improve cycle times and reduce mechanical wear.
- Lead automation-impacting projects with large or complex scope and drive strategic initiatives to improve business processes.
- Five years of pharmaceutical or biotechnology industry/GMP experience, preferably mostly in drug product, is highly preferred.
- Knowledge of GAMP5 standards and 21 CFR Part 11 requirements is highly preferred.
About the company
Genentech is a biotechnology company focused on researching and developing medicines and therapies to address unmet medical needs. It uses large-scale R&D, with about 13,500 employees and 40 approved medicines; it develops biologics and other therapies marketed through healthcare providers, generating revenue from sales. It differentiates itself with a large patent portfolio (around 20,000 patents) and multiple FDA Breakthrough Therapy Designations, along with a patient-centric approach that weighs access and affordability. Its goal is to advance medical science and deliver high-quality, effective therapies that improve patient health and support the broader medical community.
Company Size
10,001+
Company Stage
Grant
Total Funding
$47.8M
Headquarters
San Francisco, California
Founded
1976
Get referred to Genentech
See people who can refer or advise you
Simplify's Take
What believers are saying
- Hillsboro broke ground September 28, 2026 on a $750 million device fill-finish plant.
- The project adds 250 jobs and strengthens U.S. supply for oncology, neurology, immunology.
- Roche opened Boston's CVRM Innovation Center on September 17, 2026, expanding discovery capacity.
What critics are saying
- September 2026 layoffs cut 265 South San Francisco jobs, ending a 40-year plant.
- June and July 2026 cuts removed 103 gRED roles, signaling continuing research retrenchment.
- Vabysmo concentration leaves Genentech vulnerable to a retinal franchise reversal by 2027.
What makes Genentech unique
- Roche-backed Genentech pairs drug discovery with manufacturing, diagnostics, and global commercialization at scale.
- Vabysmo delivered real-world eye-disease data on September 30, 2026 across 28 countries.
- The September 24, 2026 Earendil deal shows Genentech still commands elite biotech partners.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Relocation Assistance
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -3%2 year growth
↓ -3%Sensex plunges 800 points as crop price surge fuels inflation fears across asian markets. BankBit Editorials 1 day ago 43 On the corporate front, Kyndryl released a report underscoring that enterprise leaders are increasingly prioritizing tangible business outcomes over wholesale legacy system replacement in their AI modernization strategies, signaling a maturing approach to enterprise technology investment. FTI Consulting bolstered its UK turnaround and restructuring division with four senior hires, reflecting sustained demand for advisory services amid corporate distress. Genentech presented new real-world evidence for Vabysmo at the EURETICA conference, reinforcing its positioning in the retinal therapeutics market, while Traffic safety solutions provider Kataline filed IPO papers with Sebi, adding to the pipeline of upcoming public listings. In the digital assets space, Stacks (STX) surged 10.9% in a single session following the appointment of co-founder Muneeb Ali as CEO of Stacks Labs, injecting renewed momentum into the Bitcoin-layer ecosystem. The day's trading closed with market participants weighing inflation risks against selective corporate catalysts, leaving sentiment fragile and directionally uncertain across both equity and commodity corridors. This Financial Briefing was curated and fact-checked by BankBit Editorial Team. It appeared first on BankB.it. Follow its Editorial Feed RSS Feed BankBit shares this Content always with CC License * homepage * Editorials * sensex plunges 800 points as crop price surge fuels inflation fears across asian markets.
Genentech presents new data at EURETINA, highlighting Vabysmo's real-world effectiveness and safety across major retinal conditions. * New real-world results for Vabysmo in wet AMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals * Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care * With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide. South San Francisco, CA - September 30, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo(R)(faricimab-svoa) in wet age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, with vision gains and robust anatomical improvements in untreated eyes and stable or improved vision with improved anatomical outcomes in previously treated eyes. In the wet AMD and DME cohorts of the study, vision and central subfield thickness (CST) improved in previously untreated eyes, while vision remained stable and CST improved in previously treated eyes, after 12 months of Vabysmo treatment. In RVO, both subtypes of the disease showed improvements in efficacy in people treated with Vabysmo. In the central/hemi-RVO cohort, vision and CST improved in both previously untreated and treated eyes after six months of Vabysmo therapy. In the branch RVO cohort, vision and CST improved in previously untreated eyes, while vision remained stable and CST improved in previously treated eyes, after six months of Vabysmo treatment. The data are being presented at the EURETINA 2026 Annual Meeting in Vienna, Austria. "These real-world results underscore how the efficacy and safety observed in our pivotal Vabysmo studies translate directly into routine clinical practice globally," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "The sustained visual improvements and meaningful anatomical drying seen in the VOYAGER study reinforce the role of Vabysmo in helping to address important unmet needs for patients with retinal conditions." "In daily clinical practice, we manage diverse patient populations with complex treatment histories who don't always mirror the strict entry criteria of controlled Phase III trials." said Professor Robyn Guymer, Chair of the VOYAGER Steering Committee and Deputy Director of the Centre for Eye Research Australia. "The latest VOYAGER data give physicians from across the world the confidence that Vabysmo delivers sustained visual gains, meaningful anatomical drying, and an established safety profile in everyday practice - whether a patient is starting treatment for the first time or transitioning from another therapy." The new VOYAGER real-world data in wet AMD, DME and RVO are consistent with previous Phase III study results and demonstrate the effectiveness, durability and safety of Vabysmo across diverse global practices. Across all cohorts of the study, the presence of subretinal fluid (SRF) or intraretinal fluid (IRF) was consistently reduced in previously untreated and treated eyes. In the wet AMD and DME groups, fewer Vabysmo injections were received during months 7-12 compared with months 1-6, suggesting extension of treatment intervals. | / | Mean change in visual acuity (VA) Early Treatment Diabetic Retinopathy Study (ETDRS) letters | Mean change in central subfield thickness (CST) μm | Presence of subretinal fluid (SRF) % of eyes | Presence of intraretinal fluid (IRF) % of eyes | | Wet AMD (after 12 months of Vabysmo treatment) | | No prior treatment | +4.6 | -110.5 | 72.1 | 25.3 | 48.5 | 20.6 | | Previously treated | -0.1 | -26.1 | 61.6 | 37.9 | 35.4 | 25.0 | | DME (after 12 months of Vabysmo treatment) | | No prior treatment | +8.2 | -127.8 | 26.5 | 6.8 | 87.3 | 58.1 | | Previously treated | +2.7 | -71.3 | 22.1 | 9.3 | 80.5 | 68.1 | | Branch RVO (after 6 months of Vabysmo treatment) | | No prior treatment | +10.0 | -171.3 | 36.3 | 11.8 | 83.8 | 50.0 | | Previously treated | +2.0 | -59.0 | 15.9 | 6.6 | 82.6 | 80.3 | | Central/hemi-RVO (after 6 months of Vabysmo treatment) | | No prior treatment | +16.6 | -287.4 | 50.7 | 9.8 | 85.7 | 29.4 | | Previously treated | +3.9 | -63.4 | 14.9 | 10.3 | 89.4 | 74.4 | In VOYAGER, the Vabysmo safety profile was generally consistent with that established in the Phase III studies in wet AMD, DME and RVO. About VOYAGER VOYAGER is the largest global, prospective, non-interventional real-world study of Vabysmo (faricimab-svoa). It captures real-world data from 28 countries/regions across six continents representing more than 5,000 patients treated for wet age-related macular degeneration (AMD), diabetic macular edema (DME) or retinal vein occlusion (RVO). The study leverages state-of-the-art AI and deep learning algorithms to evaluate SD-OCT images captured during routine clinical practice. About Vabysmo(R)(faricimab-svoa) Vabysmo is the first bispecific antibody approved for the eye. It targets and inhibits two signaling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilize blood vessels. Vabysmo is approved in more than 100 countries around the world, including the United States (U.S.), Japan, the United Kingdom and the European Union (E.U.) for people with neovascular or 'wet' age-related macular degeneration and diabetic macular edema, and in more than 60 countries, including the U.S., E.U. and Japan, for people with macular edema following retinal vein occlusion (RVO). Review by other health authorities is ongoing. Vabysmo U.S. Indications Vabysmo (faricimab-svoa) is a prescription medicine given by injection into the eye, used to treat adults with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Important Safety Information Contraindications Vabysmo is contraindicated in patients who have an infection in or around their eye, have active swelling around their eye that may include pain and redness, or are allergic to Vabysmo or any of the ingredients in Vabysmo. Warnings and Precautions * Injections like the one for Vabysmo can cause an eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment). Patients should seek medical care if they experience increasing eye pain, vision loss, sensitivity to light, or redness in the white of the eye. * Vabysmo may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs 60 minutes after the injection. * Although not common, Vabysmo patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with Vabysmo reported such an event. In DME studies from baseline to week 100, 64 out of 1,262 patients treated with Vabysmo reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with Vabysmo reported such an event. * Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of Vabysmo. Healthcare providers should discontinue treatment with Vabysmo in patients who develop these events. Patients should be instructed to report any change in vision without delay. Adverse Reactions The most common adverse reactions (>=5%) reported in patients receiving Vabysmo were cataract (15%) and blood on the white of the eye (conjunctival hemorrhage, 8%). These are not all the possible side effects of Vabysmo. Pregnancy, Lactation, Females and Males of Reproductive Potential * Based on how Vabysmo interacts with your body, there may be a potential risk to an unborn baby. Patients should use birth control before their first injection, during their treatment with Vabysmo, and for 3 months after their last dose of Vabysmo. * It is not known if Vabysmo passes into breast milk. Patients should talk to their healthcare provider about the best way to feed their baby if they receive Vabysmo. Patients may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Patients may also report side effects to Genentech at (888) 835-2555. Please see additional Important Safety Information in the full Vabysmo Prescribing Information or visit https://www.Vabysmo.com. About Genentech in Ophthalmology Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and other retinal diseases, including rare and inherited conditions. About Genentech Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
Genentech breaks ground on major factory project in Hillsboro. Officials projected a jubilant spirit, framing the news as a good portent for a state whose economy continues to lag. September 30, 2026 6:00AM PDT Biotech leaders and politicians descended on Hillsboro this week to celebrate the groundbreaking of a new $750 million factory expansion by biotech company Genentech. Cameras clicked as officials smiled and symbolically shoveled dirt into the air, touting the news as a good portent for a state whose economy has been lagging behind the rest of the nation for years. Genentech is not new to the area; it has had a manufacturing presence in Hillsboro for two decades, with a complex that now sprawls across several buildings. It projects the new factory will open in 2031. Officials say it will manufacture a broad range of medicines across oncology, neurology and immunology. Specific terms of the state's deal with Genentech remain unclear. Gov. Tina Kotek's office has said the agreement includes "a forgivable loan from the Governor's Strategic Reserve Fund" to help offset some of the initial capital investment costs for the project, but a spokesperson declined to offer specifics, saying final contract negotiations remain ongoing. (For context, Oregon's current two-year budget allotted the Strategic Reserve Fund about $15 million, some of which has already been allocated.) Genentech CEO Ashley Magargee, who flew in for the Monday groundbreaking, tells WW the biggest factors for the company when siting a factory are: (1) Does the area have a skilled workforce? (2) Can Willamette Week work with good state and local leaders on issues like permitting and logistics? And (3) will the community embrace them? Asked how Oregon could improve its performance, Magargee said the state had "nailed it." In key measures like job growth, Oregon continues to rank poorly, state economists have found. The health services sector continues to be the state's primary driver of job creation - mirroring national trends that in part simply reflect that the population is aging. But other sectors have not seen this kind of growth at all. For example: Though the semiconductor industry has boomed nationwide amid a massive buildout in artificial intelligence infrastructure, the Bureau of Labor Statistics estimates that employment in Oregon's semiconductor and electronic product manufacturing industry fell 28% between January 2023 and June 2026. Kotek, who is deep in a tough reelection campaign, was among the officials who projected a jubilant spirit this week. She noted the huge recent pledges from Phil and Penny Knight to the Oregon Health & Science University's Knight Cancer Institute and, more recently, to the University of Oregon to establish a college of engineering. "We are on a roll, people," she told Genentech employees and other attendees in remarks before the groundbreaking. Kotek's office describes Oregon as a leader in the life sciences sector, noting the presence of other firms like Thermo Fisher and Lonza. In an interview with WW as the Genentech event was wrapping, Kotek framed the deal as part of a longer-term project to further build out the life sciences workforce and industry in Oregon, saying a focus of the next two years would be to partner with high schools and higher ed to build out the talent pipeline. "This," she said, "is the next stage of manufacturing for our state." Andrew Schwartz writes about health care. He's spent years reporting on political and spiritual movements, most recently covering religion and immigration for the Chattanooga Times Free Press, and before this as a freelancer covering labor and public policy for various magazines. He began his career at the Walla Walla Union-Bulletin. Willamette Week's reporting has real-life impact that changes laws, forces action by civic leaders, and drives compromised politicians from public office. Help Willamette Week dig deeper.
Its pipeline. Monday, Sep 28, 2026 Genentech breaks ground on $750 million manufacturing expansion in Hillsboro, Oregon. * Expansion adds 211,000 square feet to the site, supported by approximately 200 construction jobs * Investment creates approximately 250 high-wage jobs pairing manufacturing expertise with digital skills in AI, automation and robotics * New facility brings device fill-finish capabilities to Genentech's manufacturing network - expanding on established fill-finish operations - and builds on recent manufacturing and investment milestones in Holly Springs, North Carolina and Boston, Massachusetts. South San Francisco, CA - September 28, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today broke ground on a $750 million expansion of its manufacturing facility in Hillsboro, Oregon, advancing plans announced in August to increase capacity for advanced drug delivery devices and to strengthen the company's United States manufacturing capabilities. The event marks the start of construction for the 211,000-square-feet expansion, doubling the size of the existing site. Commercial operations are planned to begin in 2031. Once operational, the expanded facility will add device fill-finish capabilities, including the manufacturing of combination products, to Genentech's U.S. manufacturing network. With flexible high- and low-volume filling capabilities, the site is designed to manufacture a broad range of medicines across oncology, neurology and immunology. This added capacity will help strengthen Genentech's domestic supply chain and support reliable access to medicines for patients. The expansion will create approximately 250 high-wage manufacturing jobs. Over the coming years, Genentech will recruit for specialized roles across filling and inspection, device assembly and packaging, cold storage, and quality control. These roles will pair traditional manufacturing expertise with digital skills in AI, automation and robotics, creating a modern workforce equipped to drive innovation in precision manufacturing. Construction of the facility will also support approximately 200 additional construction jobs. Genentech established its Hillsboro campus in 2006. Today, the 75-acre campus is an important part of the company's manufacturing network, with capabilities spanning drug product manufacturing, packaging, distribution and individualized therapies. The decision to expand in Hillsboro reflects Genentech's continued confidence in the area's experienced workforce, established infrastructure and manufacturing expertise, as well as the company's longstanding partnership with the Hillsboro community and the state of Oregon. The expansion is part of Roche and Genentech's investment commitment in U.S. manufacturing and R&D and builds on recent manufacturing and investment milestones in Holly Springs, North Carolina and Boston, Massachusetts. Together, these investments expand an end-to-end U.S. footprint spanning research, development and manufacturing and reflect the companies' long-term commitment to American scientific innovation. Roche and Genentech have approximately 25,000 employees in the U.S., with 15 R&D centers and 13 manufacturing sites. Genentech CEO Ashley Magargee: "Breaking ground in Hillsboro turns our commitment into action. For 20 years, the talented team here has played an important role in manufacturing and delivering medicines for patients, and this expansion builds on that strong foundation. As construction begins we are one step closer to bringing device fill-finish manufacturing to Hillsboro, strengthening our domestic supply chain and investing in the people and infrastructure that will help us deliver the medicines of the future." Susanne Hundsbaek-Pedersen, Roche EVP of Pharma Technical Operations: "The medicines in our pipeline increasingly include devices that improve delivery convenience and our manufacturing network is evolving to service these requirements. This manufacturing expansion in Hillsboro will add capabilities that our future portfolio will need, along with the flexibility to adapt as patient needs change. The site will feature advanced digital technology, AI, automation, and robotics to optimize production, as well as an exact digital twin for real-time monitoring and continuous improvement. Combined with the expertise already on this site, it will strengthen how we supply medicines across our global network." Tina Kotek, Governor of Oregon: "Today, we're seeing a major investment in Oregon move from plans on paper to breaking ground. Genentech's continued growth in Hillsboro demonstrates the strength of Oregon's workforce and our ability to support advanced manufacturing that is important to both our state and the country. This project will create new opportunities for Oregonians while strengthening Hillsboro's role in the future of U.S. medicine manufacturing." Beach Pace, Mayor of Hillsboro: "Today's groundbreaking is an exciting moment for Hillsboro and a sign of what's ahead for our city. Projects of this scale are made possible by strong partnerships across the community, from the people who will build this facility to the local organizations and institutions that support a skilled workforce that will staff the facility, and of course, between the City of Hillsboro and Genentech. We look forward to this next chapter taking shape and continuing to build Hillsboro's and Genentech's future together." About Genentech Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
Roundup: Nanexa, Earendil Labs, and Atavistik Bio enter platform deals with Novo Nordisk, Genentech, and Roche. Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines. Platform-technology deals dominated this week's dealmaking, as drug delivery and discovery specialists licensed their proprietary systems to larger partners chasing next-generation metabolic and oncology medicines. Nanexa licenses Pharmashell platform to Novo Nordisk. Nanexa AB entered into a global exclusive license and collaboration agreement with Novo Nordisk for the use of the Pharmashell technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes, and other cardiometabolic indications. As part fo the deal, Nanexa is eligible to receive total payments upwards of $1.33 billion, including $701 million in upfront payment and development and regulatory milestones, with the remaining milestone payments tied to sales.[1] Nanexa is also eligible to receive low single-digit royalties on global net sales of products developed under the agreement.[1] Under terms of the agreement, Novo is expected to receive a global license to use Nanexa's Pharmashell technology platform in up to five development programs.[1] The collaboration includes development of long-acting injectable formulations with different administration-frequency profiles, with monthly and quarterly administration as target profiles. Pharmashell is Nanexa's proprietary atomic layer deposition-based drug delivery platform, designed to enable controlled and sustained release of active pharmaceutical ingredients through an ultra-thin inorganic coating applied to individual drug particles, intended to support differentiated long-acting injectable drugs that reduce dosing frequency and improve the treatment experience for people living with chronic metabolic or cardiovascular disease.[1] "We are very excited about and proud of this license agreement with Novo and look forward to working with them to successfully develop products with less frequent dosing in obesity and type 2 diabetes indications. Following our license and option agreement with Moderna in 2025, this agreement further strengthens the external validation of Pharmashell as a broadly applicable drug delivery platform and we believe this provides a strong foundation for expanding Pharmashell into additional therapeutic areas and to selectively advance additional internal programs towards clinical proof of concept, allowing us to capture greater value from the breadth of the Pharmashell platform," said David Westberg, CEO of Nanexa. Earendil Labs partners with Genentech. Earendil Labs announced a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody programs in oncology. Earendil Labs will receive a $55 million upfront payment, and the total potential value of the collaboration, including upfront, development, regulatory and sales milestone payments is expected to excess $1.5 billion.[2] Earendil Labs is also eligible to receive tiered royalties on net product sales. Under the collaboration, Earendil Labs will lead antibody discovery and research through the early clinical development stage for antibody programs directed to certain pre-agreed target combinations, while Genentech will assume responsibility for subsequent global clinical development and commercialization of antibody programs arising from the collaboration.[2] "Genentech is a pioneer in defining modern biologics cancer medicine. Earendil Labs is building an AI-driven high-throughput biology platform that effectively integrates AI directly into biologics research and development - from predictive protein modeling and generative protein design to rapid experimental validation. By combining our platform with Genentech's deep expertise in oncology drug development, we aim to accelerate the creation of differentiated bispecific antibodies and translate them into new medicines," said Jian Peng, PhD, CEO of Earendil Labs. Atavistik Bio strikes CVRM discovery collaboration with Roche. Atavistik Bio entered into a strategic research collaboration with Roche to discover and develop novel small molecule therapeutics against multiple targets for cardiovascular, renal, and metabolic diseases. As part of the deal, Atavistik Bio is set to receive an upfront payment of $70 million and may be eligible to receive additional research, development, and commercial milestone payments of up to $1.9 billion, along with tiered royalties on future net sales of any approved medicines resulting from the collaboration.[3] The collaboration will leverage Atavistik Bio's proprietary Amps drug discovery platform and expertise in allosteric drug discovery to identify novel functional binding pockets and advance selective small molecule therapeutics against targets for cardiovascular, renal, and metabolic disease.[3] By uncovering cryptic, biologically relevant binding pockets, Atavistik Bio's platform enables new approaches to develop differentiated small molecules against therapeutically important targets that have historically been challenging to modulate. Under the terms of the agreement, Atavistik Bio will be responsible for discovery and research activities for the collaboration targets, with Roche responsible for further preclinical and clinical development, regulatory, and commercialization activities.[3] "We are pleased to partner with Roche, whose deep expertise in drug development makes them an ideal partner to extend the reach of our allosteric discovery platform," said Bryan Stuart, chief executive officer of Atavistik Bio. "This collaboration reflects the strength and broad applicability of our platform across therapeutic areas, further validating our approach to allosteric drug discovery. We are excited to extend the application of our platform into CVRM diseases by leveraging Roche's deep expertise in the field, while we remain focused internally on advancing a robust pipeline of potentially best-in-class therapies for patients with rare hematologic diseases."